Personalized Diabetes Therapy Part 1-Functional Phenotyping as a Conceptual Basis for Individualized Treatment

Andreas Pfützner1,2,3, Julia Jantz1

  • 1Pfützner Science & Health Institute, D-55128 Mainz, Germany.

Insights

Classical type 2 diabetes diagnosis lacks pathophysiological insight. This paper introduces a personalized phenotyping method for tailored diabetes therapies, moving beyond symptom classification for better treatment selection.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Personalized Medicine

Background:

  • Current type 2 diabetes diagnosis relies on clinical markers (HbA1c, glucose, lipids, BMI, blood pressure), offering limited insight into underlying pathophysiology.
  • Pathophysiological disorders like insulin resistance, beta-cell dysfunction, and chronic inflammation are key to understanding disease progression.
  • A deeper understanding of these disorders is crucial for developing effective, personalized therapeutic interventions.

Purpose of the Study:

  • To present a novel method for individual phenotyping in type 2 diabetes.
  • To describe the pathophysiological background and diagnostic approach for this phenotyping method.
  • To lay the groundwork for personalized diabetes therapy based on individual patient phenotypes.

Main Methods:

  • Development of a personalized phenotyping method based on extensive clinical trial experience.
  • Focus on understanding underlying pathophysiological disorders beyond standard diagnostic biomarkers.
  • Description of the diagnostic approach for phenotyping in Part 1 of this series.

Main Results:

  • The presented method aims to classify patients based on distinct pathophysiological profiles.
  • This phenotyping approach moves beyond traditional symptom-based diagnosis.
  • It facilitates a more targeted selection of personalized therapeutic strategies.

Conclusions:

  • Traditional type 2 diabetes diagnosis needs enhancement with pathophysiological insights.
  • Individualized phenotyping offers a pathway to more precise and potentially successful diabetes management.
  • Further prospective validation studies are required to confirm the clinical utility of this phenotype-based framework.

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

1.5K
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
388
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
157
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
119